Home  »  News   »  Gear up for the change! Chinook Therapeutics Inc. ...

Gear up for the change! Chinook Therapeutics Inc. (KDNY) has hit the volume of 365685

For the readers interested in the stock health of Chinook Therapeutics Inc. (KDNY). It is currently valued at $21.42. When the transactions were called off in the previous session, Stock hit the highs of $21.55, after setting-off with the price of $20.46. Company’s stock value dipped to $20.46 during the trading on the day. When the trading was stopped its value was $20.34.Recently in News on November 22, 2022, Chinook Therapeutics to Present at Upcoming Investor Conferences. Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in fireside chats and one-on-one meetings at the following upcoming investor conferences:. You can read further details here

Chinook Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $23.86 on 09/09/22, with the lowest value was $11.16 for the same time period, recorded on 01/28/22.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


Chinook Therapeutics Inc. (KDNY) full year performance was 27.27%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Chinook Therapeutics Inc. shares are logging -10.23% during the 52-week period from high price, and 91.94% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $11.16 and $23.86.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 365685 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Chinook Therapeutics Inc. (KDNY) recorded performance in the market was 31.33%, having the revenues showcasing -4.42% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.37B, as it employees total of 138 workers.

The Analysts eye on Chinook Therapeutics Inc. (KDNY)

During the last month, 0 analysts gave the Chinook Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 20.43, with a change in the price was noted +3.11. In a similar fashion, Chinook Therapeutics Inc. posted a movement of +16.99% for the period of last 100 days, recording 540,263 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for KDNY is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Technical rundown of Chinook Therapeutics Inc. (KDNY)

Raw Stochastic average of Chinook Therapeutics Inc. in the period of last 50 days is set at 60.60%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 46.83%. In the last 20 days, the company’s Stochastic %K was 21.72% and its Stochastic %D was recorded 22.75%.

Considering, the past performance of Chinook Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 31.33%. Additionally, trading for the stock in the period of the last six months notably improved by 57.62%, alongside a boost of 27.27% for the period of the last 12 months. The shares increased approximately by -0.51% in the 7-day charts and went up by -1.83% in the period of the last 30 days. Common stock shares were lifted by -4.42% during last recorded quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts